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Background: Hospital volume, surgeons’ experience, and adequate management of complications are factors that
contribute to a better outcome after pancreatic resections. The aim of our study was to analyze trends in indications,
surgical techniques, and postoperative outcome in more than 1,100 pancreatic resections.
Methods: One thousand one hundred twenty pancreatic resections were performed since 1994. The vast majority of
operations were performed by three surgeons. Perioperative data were documented in a pancreatic database. For
the purpose of our analysis, the study period was sub-classified into three periods (A 1994 to 2001/n = 363; B 2001 to
2006/n = 305; C since 2007 to 2012/n = 452).
Results: The median patient age increased from 51 (A) to 65 years (C; P < 0.001). Indications for surgery were
pancreatic/periampullary cancer (49%), chronic pancreatitis (CP; 33%), and various other lesions (18%). About two
thirds of the operations were pylorus-preserving pancreaticoduodenectomies. The frequency of mesenterico-portal
vein resections increased from 8% (A) to 20% (C; P < 0.01). The overall mortality was 2.4% and comparable in all three
periods (2.8%, 2.0%, 2.4%; P = 0.8). Overall complication rates increased from 42% (A) to 56% (C; P < 0.01).
Conclusions: Mortality remained low despite a more aggressive surgical approach to pancreatic disease. An
increased overall morbidity may be explained by more clinically relevant pancreatic fistulas and better documentation.
Keywords: Pancreatic surgery, Pancreatic resections, Indication, Morbidity, MortalityBackground
One major advance in pancreatic surgery over the past
two decades is the resection of premalignant pancreatic
lesions to prevent development of pancreatic cancer [1].
This is only possible because pancreatic resections have
developed into routine procedures with low mortality
[2]. Many factors like hospital volume, surgeons’ experi-
ence, and improved management of postoperative com-
plications are known to improve the outcome of
pancreatic surgery [3]. At the same time, pancreatic
resections are performed in patients with a higher peri-
operative risk profile.* Correspondence: uwe.wittel@uniklinik-freiburg.de
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unless otherwise stated.In our study, we analyze patient characteristics and
shifts in surgical strategies in pancreatic resections in
our clinic. Additionally, we examine the morbidity and
mortality during 18 years of surgical practice in a col-
lective of 1,120 patients who underwent resections of
the pancreas in a single institution cohort.Methods
From July 1994 to September 2012, 1,120 patients
underwent pancreatic resections for various reasons at
our institution. Pancreatic resection included pylorus-
preserving pancreatic head resections, classical Whipple
procedures, distal pancreatectomies, total pancreatecto-
mies, segmental resections, duodenum-preserving pan-
creas head resections, and central pancreatic resections.
For the purpose of analysis, three time periods wereThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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1994 to August 2001, period B includes patients from
September 2001 to December 2006, while period C in-
cludes patients from January 2007 to September 2012.
The entire team working with the senior author UTH
moved from the University of Rostock to the University
of Freiburg in September 2001 with continuity in staff
and experience.
Operative specimens underwent standard histopatho-
logical evaluation. This included documentation of
tumor size, lymph node status, and resection margin. A
negative resection margin was defined as tumor distant
to the resection margin independent of the precise
distance.
Data collection and statistics
Perioperative data was collected in a SPSS database
(SPSS, Version 21.0, SPSS Inc., Chicago, IL, USA) in ac-
cordance with the Helsinki guidelines and approved by
the local committee. Data analyses were performed in a
retrospective manner. Descriptive statistics were gener-
ated. The median age and BMI as well as the corre-
sponding 95% confidence intervals were calculated. To
investigate the amount of blood transfusions, the average
volume and the corresponding 95% CI were calculated.
Significant alterations between the groups were deter-
mined by chi-square test according to Pearson.
Results
Perioperative data was collected from 1,120 consecu-
tively treated patients of our institution from 1994 until
2012.Table 1 Patient characteristics
1994 to 2001 2001 to
Number of resections 363 305
Gender Male 245 (67.5%) Male 158
Female 118 (32.5%) Female 1
Age 51 (15 to 77) 64 (9 to 8
Body mass index 22.8 (14 to 35) 23.6 (15 t
Nicotine Not determined Yes 56 (3
No 121 (6
Not dete





Dignity of disease Benign 226 (62.3%) Benign 1
Malignant 137 (37.7%) Malignan
Number (percentage) or median (95% CI). ASA, American Society of AnesthesiologisPatient characteristics
Throughout the observed 18 years, a significant increase
in age was observed (Table 1). While the median age
was 51 (15 to 77) years during period A, the age in-
creased gradually to 64.9 (17 to 89) years in period C.
Distribution of gender shows a shift from male to female
which is due to the higher prevalence of patients with
chronic pancreatitis during period A. This also explains
the observed shift from benign to malignant diagnoses.
Epidemiologically, this may be explained by epidemio-
logical differences in disease prevalence of chronic pan-
creatitis between North and South Germany.
Pathologic diagnosis
Geographical shifts in disease prevalence explain the drop
of patients with chronic pancreatitis from 56.2% during
period A to 17.3% during period C (Table 2). In part, this
also explains the higher relative prevalence of patients
with malignancies, which increased from 22.3% to 42.3%
during the observation period. Ductal adenocarcinoma
was by far the most frequently underlying pathology in pa-
tients with malignancies, followed by ampullary carcin-
omas. A shift of disease prevalence within the collective of
patients with malignant diagnoses was not observed. In-
creasing understanding of benign and premalignant cystic
pancreatic lesions led to increased resection rates of intra-
ductal papillary mucinous neoplasms (IPMNs), beginning
at 0% between 1994 and 2001 and increasing to 7.7% dur-
ing the third period until 2012. Additionally, improved
preoperative diagnostic possibilities and further data on
premalignant cystic lesions lead to an increased rate of
resections of rare pancreatic lesions.2006 2007 to 2012 P value
452
(51.8%) Male 248 (54.9%) <0.001
47 (48.2%) Female 204 (45.1%)
4) 65 (17 to 89) <0.001
o 36) 24.4 (15 to 41) <0.001
1.6%) Yes 121 (27.5%) Not significant
8.4%) No 319 (72.5%)
rmined 128 Not determined 12
) I 30 (6.9%) Not significant
.7%) II 242 (55.8%)
0%) III 153 (35.3%)
) IV 9 (2.1%)
rmined 136 Not determined 18
09 (35.7%) Benign 163 (36.1%) <0.001
t 196 (64.3%) Malignant 289 (63.9%)
ts.
Table 2 Histologic diagnosis
1994 to 2001 2002 to 2006 2007 to 2012
Malignoma
Ductal adenocarcinoma 81 (22.3%) 108 (35.4%) 191 (42.3%)
Distal bile duct cancer 13 (3.6%) 29 (9.5%) 15 (3.3%)
Ampullary carcinoma 25 (6.9%) 29 (9.5%) 34 (7.5%)
Duodenal carcinoma 2 (0.6%) 9 (3.0%) 4 (0.9%)
Pancreatic neuroendocrine
tumor
6 (1.7%) 13 (4.3%) 29 (4.3%)
Metastases 4 (1.1%) 5 (1.6%) 9 (2.0%)
Benign tumors
IPMN 0 (0%) 7 (2.3%) 35 (7.7%)
Chronic pancreatitis 204 (56.2%) 83 (27.2%) 78 (17.3%)
Others 28 (7.7%) 22 (7.2%) 57 (12.6%)
Number (percentage). IPMN, intraductal papillary mucinous neoplasm.
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Eighty-one percent of procedures were performed by
three main surgeons. The caseload of these surgeons
was 291, 292, and 317, respectively. Two hundred twenty
pancreatic resections were performed by less experi-
enced surgeons. The annual number of resections of the
pancreas increased gradually from an average of 51 re-
sections per year during the years 1994 to 2001 to 57
per year from 2001 to 2006 up to 95 resections per year
from 2007 to 2012 (Table 3).
Due to the reduced rate of patients with chronic
pancreatitis, the frequency of duodenum-preserving re-
sections decreased from 18.5% to 3.5%. The rate of pan-
creaticoduodenectomies remained unaltered, while the
rates of total pancreatectomies and distal pancreatecto-
mies increased from 1.4% to 6.6% and from 11.6% to
23.2%, respectively. The rate of venous resections in-
creased from 7.7% in period A to 19.7% in period C.Table 3 Surgical procedures and experience of surgeon
1994 to 2001
Resections
Annual number of resections 51
Whipple procedure 51 (14.0%)
Pylorus-preserving pancreaticoduodenectomy 193 (53.2%)
Duodenum-preserving pancreatic head resection 67 (18.5%)
Distal pancreatectomy 42 (11.6%)
Total pancreatectomy 5 (1.4%)
Segmental resection 4 (1.1%)
Central resection 0 (0%)
PV resection 28 (7.7%)
Laparoscopic procedure 0 (0%)
Number (percentage). PV, portal vein.Laparoscopic resections of the pancreas were intro-
duced during period C. In period C, 10% of resections
were performed in a laparoscopically assisted technique.
In these cases of pancreaticoduodenectomy, the resec-
tion was performed in a laparoscopic manner while re-
construction was achieved via mini laparotomy. Distal
pancreatectomies were performed as fully laparoscopic
procedures.
Morbidity and mortality
The mortality rates during all three periods were low at
2.8%, 2.0%, and 2.4%, respectively (Table 4). However,
the surgery-related morbidity increased from 28.7% to
50.7%. Interestingly, the reoperation rate did not change
significantly. An increased rate of pancreatic fistulas is
one reason explaining the increase of morbidity. Partly,
this is due to the relative increase of resections of pan-
creatic malignancies or premalignant lesions in patients
with soft pancreatic texture, while there was a decrease
of resections of patients with chronic pancreatitis. Add-
itionally, the documentation of postoperative complica-
tions like pancreatic fistulas was improved due to the
initiation of prospective studies.
Morbidity and mortality in dependency of diagnosis
Morbidity and mortality were influenced by the histo-
pathological diagnosis, and two distinct deviations were
apparent (Table 5). The rate of reoperations was higher
in patients with IPMNs when compared to patients with
other pathohistological diagnoses. While the main rea-
sons for reoperations in these patients were postopera-
tive hemorrhage and leakage of the biliary anastomosis,
a possibly increased risk for the leakage of the biliary
anastomosis could be explained by the usually non-
dilated bile duct in these patients. The second observa-
tion was that the rate of pancreatic fistulas was highest2002 to 2006 2007 to 2012 P value
57 95 Not significant
23 (7.5%) 35 (7.7%) Not significant
180 (59.0%) 259 (57.3%) Not significant
41 (13.4%) 16 (3.5%) Not significant
52 (17.0%) 105 (23.2%) Not significant
7 (2.3%) 30 (6.6%) <0.001
2 (0.7%) 4 (0.8%) Not significant
0 (0%) 3 (0.6%) Not significant
59 (19.3%) 89 (19.7%) <0.001
0 (0%) 53 (11.7%) <0.001
Table 4 Morbidity and mortality
1994 to 2001 2002 to 2006 2007 to 2012 P value
Mortality 10 (2.8%) 6 (2.0%) 11 (2.4%) Not significant
Overall morbidity 151 (41.6%) 170 (55.7%) 257 (56.9%) <0.001
Operation-related morbidity 104 (28.7%) 111 (36.4%) 229 (50.7%) <0.001
Reoperation 33 (9.1%) 33 (10.8%) 61 (13.5%) Not significant
Transfusion
Number of patients with transfusion 313 (87.5%) 66 (21.6%) 87 (19.3%) <0.001
Average volume 1,523 (1,345 to 1,701) ml 170 (124 to 217) ml 177 (129 to 227) ml <0.001
Pancreatic fistula grades A to C 37 (10.2%) 79 (25.9%) 180 (39.8%) <0.001
Number (percentage) or average (95% CI).
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other pathohistological entities. This may be explained
by the high rate of distal and atypical pancreatic resec-
tions in these patients.
Discussion
Our data mirrors several epidemiological developments
and the expansion of indications of pancreatic resections
over the past 18 years. One very interesting insight
provided by this study is the correlation between the
dramatic change of the prevalence rates of chronic pan-
creatitis with the geographical relocation of the main
surgeons. Such regional shifts have been observed in the
past and are believed to be linked to nutritional habits
as well as differences in alcohol and possibly nicotine
consumption [4,5]. Therefore, the rate of pancreatic re-
sections due to benign diseases was higher during period
A when compared to period C. For the same reason, the
age of the patients increased over time since patients
suffering from chronic pancreatitis have a median age in
the 40s, and the age of patients with pancreatic cancer
averages in the 60s [6,7].
The analysis of the diagnosis obtained after pancreatic
resections sheds light on several developments. For one,
it confirms the increase in pancreatic cancer cases men-
tioned above. Furthermore, the number of pancreatic
resections performed due to premalignant lesions in-
creased substantially from 0% to 7.7%. This occurredTable 5 Morbidity and mortality in dependency of diagnosis
PDAC Periampullary carcinoma
(n = 380) (n = 160)
Mortality 16 (4.2%) 4 (2.5%)
Overall morbidity 194 (51.1%) 101 (63.1%)
Operation-related morbidity 131 (34.5%) 76 (47.5%)
Reoperation 40 (10.5%) 21 (13.1%)
Pancreatic fistula grades A to C 70 (18.4%) 62 (38.8%)
Number (percentage). PDAC, pancreatic ductal adenocarcinoma; pNET, primitive nedue to accumulation of data on benign cystic pancreatic
lesions and subsequently adjusted treatment guidelines
developed during the observation period, such as the
Sendai guidelines [8]. However, even before the publica-
tion of these guidelines in 2006, an increase in pancre-
atic resections due to IPMNs was observed between
2001 and 2006. This indicates that even before the publi-
cation of these consensus guidelines, resections of pre-
malignant lesions were regularly performed.
In terms of surgical procedures, duodenum-preserving
techniques decreased substantially due to a reduced
number of chronic pancreatitis cases, while at the same
time, the number of distal pancreatectomies and total
pancreatectomies increased substantially. Similar to
other patient collectives, the increase in pancreatecto-
mies was mostly due to an increased number of resec-
tions of main-duct-type IPMNs and the resection of
larger carcinomas located in the pancreatic body [9].
The increase of distal pancreatectomies was mostly due
to increased resections of not only benign but also ma-
lignant pancreatic lesions.
During the first two periods from 1994 until 2006, no
laparoscopic resections were performed in our center.
During the last period, there was a substantial increase
in laparoscopic procedures. These included distal pan-
createctomies with and without preservation of the
spleen as well as laparoscopy-assisted pancreaticoduode-
nectomies. In the latter cases, the reconstruction wasChronic pancreatitis pNET IPMN Other P value
(n = 360) (n = 48) (n = 42) (n = 125)
5 (1.4%) 0 (0.0%) 2 (4.8%) 0 (0.0%) <0.05
161 (44.1%) 22 (45.8%) 25 (59.5%) 75 (60.0%) <0.001
121 (33.2%) 23 (47.9%) 23 (54.8%) 70 (56.0%) <0.001
35 (9.6%) 6 (12.5%) 11 (26.2%) 14 (11.2%) <0.05
68 (18.6%) 23 (47.9%) 15 (35.7%) 58 (46.4%) <0.001
uroectodermal tumor; IPMN, intraductal papillary mucinous neoplasm.
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groups [10,11].
While mortality rates and the rate of reoperations
remained low, the morbidity increased over time. Several
factors are responsible for the increased rate of compli-
cations, both surgical complications as well as complica-
tions not directly linked to surgery. Most surgery-related
complications were pancreatic fistulas and delayed gas-
tric emptying. The greater number of pancreatic fistulas
is due to several developments: the resection of more
patients with non-malignant disease, fewer chronic pan-
creatitis cases, better documentation of fistulas, and
publication of international guidelines in 2005 [12]. Sec-
ondly, an increase in delayed gastric emptying was ob-
served which occurred due to the implementation of
pancreaticogastrostomies for pancreatic reconstruction
which are associated with increased rates of delayed gas-
tric emptying compared to pancreaticojejunostomies
[13]. A further increase in morbidity can be explained by
the increased patient age and a higher rate of non-
surgery-related complications. Furthermore, there was
an increase of resections of advanced malignancies
which can be observed by an increase in portal vein re-
sections. The latter was not associated with a higher
morbidity in our collective, while larger studies show
that venous resection is associated with increased mor-
bidity rates [14].
Conclusions
We are able to demonstrate that pancreatic resection at
a high-volume center is a safe procedure with a low
mortality rate and low rates of reoperations. Operative
mortality in our high-volume institutional series of more
than 1,100 pancreatic resections remained low despite a
more aggressive surgical approach to pancreatic disease.
However, pancreatic resections still have a substantial
morbidity that is mainly driven by the occurrence of
pancreatic fistulas. The rate of surgical complications,
however, is responsible for increased length of hospital
stay and increased rates of readmission and therefore is
the main driving force of increased treatment costs of
patients undergoing pancreatic resections [15].
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